Sign In
Buy INSM
$106.92
-0.490 (-0.456%)
At Close: Jul 24, 2026
Nasdaq-100 Shake-Up: These 6 Stocks Are In, 6 Are Out — And It Could Trigger Big Moves
06:01am, Monday, 15'th Dec 2025
The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, effective December 22, 2025.
Insmed, Inc. $INSM Shares Sold by Castleark Management LLC
04:06am, Monday, 15'th Dec 2025
Castleark Management LLC trimmed its position in shares of Insmed, Inc. (NASDAQ: INSM) by 94.2% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional invest
Alkeon Capital Management LLC Invests $50.32 Million in Insmed, Inc. $INSM
03:59am, Saturday, 13'th Dec 2025
Alkeon Capital Management LLC purchased a new stake in shares of Insmed, Inc. (NASDAQ: INSM) during the second quarter, according to the company in its most recent 13F filing with the Securities and E
California Public Employees Retirement System Trims Stake in Insmed, Inc. $INSM
04:30am, Friday, 12'th Dec 2025
California Public Employees Retirement System lessened its position in Insmed, Inc. (NASDAQ: INSM) by 16.3% in the second quarter, according to the company in its most recent filing with the Securitie
Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks
09:11am, Thursday, 11'th Dec 2025
Stanley Druckenmiller is a Wall Street legend whose trades are truly worth tracking due to how consistently he has been winning.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Thursday, 04'th Dec 2025
BRIDGEWATER, N.J. , Dec. 4, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
American Century Companies Inc. Sells 682,059 Shares of Insmed, Inc. $INSM
03:14am, Wednesday, 03'rd Dec 2025
American Century Companies Inc. lowered its stake in shares of Insmed, Inc. (NASDAQ: INSM) by 78.2% during the second quarter, according to the company in its most recent Form 13F filing with the Secu
Insmed Incorporated (INSM) Presents at Evercore 8th Annual Healthcare Conference Transcript
12:53pm, Tuesday, 02'nd Dec 2025
Insmed Incorporated (INSM) Presents at Evercore 8th Annual Healthcare Conference Transcript
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks
03:14am, Sunday, 30'th Nov 2025
Druckenmiller invests his personal and family's wealth through his fund, the Duquesne Family Office. Druckenmiller is high on biotech stocks, with his top three holdings at the end of the third quarte
Insmed (NASDAQ:INSM) Hits New 12-Month High – Should You Buy?
03:48am, Friday, 28'th Nov 2025
Insmed, Inc. (NASDAQ: INSM - Get Free Report) shares hit a new 52-week high during trading on Wednesday. The company traded as high as $209.77 and last traded at $209.02, with a volume of 2093177 shar
This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He's Buying Now.
11:38am, Monday, 24'th Nov 2025
Stanley Druckenmiller has been one of the most successful investors, a billionaire with a long record of high returns in global macro investing.
Insmed (NASDAQ:INSM) Stock Unloaded Rep. Gilbert Ray Cisneros, Jr.
02:15am, Friday, 21'st Nov 2025
Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Insmed, Inc. (NASDAQ: INSM). In a filing disclosed on November 18th, the Representative disclosed that they had sold bet
Catalyst Funds Management Pty Ltd Purchases Shares of 47,175 Insmed, Inc. $INSM
05:14am, Thursday, 20'th Nov 2025
Catalyst Funds Management Pty Ltd purchased a new stake in Insmed, Inc. (NASDAQ: INSM) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 47,175 s
Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri
12:01pm, Wednesday, 19'th Nov 2025
INSM climbs after the EU clears Brinsupri as the first approved treatment for NCFB, backed by phase III ASPEN and phase II WILLOW results.
— Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI Is a First-in-Disease, First-in-Class DPP1 Inhibitor Tar
